Results 71 to 80 of about 6,391 (198)

Implementing Pre‐Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects

Clinical Pharmacology &Therapeutics, EarlyView.
In pediatric oncology, pharmacogenetic guidelines are underutilized and the potential impact of pre‐emptive pharmacogenetic screening remains largely unexplored despite this field's need for individualized approaches. While comprehensive pharmacogenetic guidelines are not yet available for all anticancer drugs, evidence‐based recommendations exist for ...
Emma C. Bernsen, Eugène T.P. Verwiel, Maaike van der Lee, Jesse J. Swen, Marcel Santoso, Leiah J. Brigitha, Rick Admiraal, Bastiaan B.J. Tops, Alwin D.R. Huitema, Patrick Kemmeren, Jayne Y. Hehir‐Kwa, Lidwien M. Hanff, Meta H.M. Diekstra   +12 more
wiley   +1 more source

Acute lymphoblastic leukemia in adolescents and young adults in Finland

Haematologica, 2008
Background Interest has recently been paid to adolescents and young adults with acute lymphoblastic leukemia, particularly because all reports so far published indicate that these patients have a better outcome when treated with pediatric rather than ...
Anu Usvasalo, Riikka Räty, Sakari Knuutila, Kim Vettenranta, Arja Harila-Saari, Esa Jantunen, Marjut Kauppila, Pirjo Koistinen, Katriina Parto, Pekka Riikonen, Toivo T. Salmi, Raija Silvennoinen, Erkki Elonen, Ulla M. Saarinen-Pihkala   +13 more
doaj   +1 more source

Characterization of Apixaban Pharmacokinetics/Pharmacodynamics and Dose Assessment in Pediatric Patients with Congenital or Acquired Heart Disease

Clinical Pharmacology &Therapeutics, EarlyView.
Apixaban is an oral direct inhibitor of factor Xa (FXa) that could be a treatment option for thromboembolism prevention in children with congenital or acquired heart disease (CAHD). Data from SAXOPHONE, a phase II pediatric study, were used to update a previously developed population pharmacokinetics (PPK) model and to assess the covariate effect of ...
Antoinette Ajavon‐Hartmann, Praneeth Jarugula, Hyunmoon Back, Obinna Obianom, Elizabeth Ludwig, Christina Crevar, David Marchisin, Zhaoqing Wang, Weidong Chen, Bing He, R. Mark Payne, Kristin M. Burns, Andrew C. Glatz, Christoph Male, Paul Monagle, Vidya Perera, Bindu Murthy, Samira Merali   +17 more
wiley   +1 more source

Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges

Clinical Pharmacology &Therapeutics, EarlyView.
Barriers to incorporating pharmacogenetics into routine clinical practice in the United States are well documented. Initial surveys by the Clinical Pharmacogenetics Implementation Consortium (CPIC) in 2009 and 2010 identified barriers across four key domains that have hindered the widespread adoption of clinical pharmacogenetic testing.
D. Max Smith, Michael P. Douglas, Christina L. Aquilante, Patricia A. Deverka, Beth Devine, Henry M. Dunnenberger, Philip E. Empey, Daniel L. Hertz, Andrew A. Monte, Ann M. Moyer, Jai N. Patel, Victoria M. Pratt, Loren Saulsberry, Stuart A. Scott, Deepak Voora, Erica L. Woodahl, Michelle Whirl‐Carrillo, Akinyemi Oni‐Orisan, on behalf of the Pharmacogenomics Global Research Network (PGRN) Publications Committee   +18 more
wiley   +1 more source

Mutations of PHF6 are associated with mutations of NOTCH1, JAK1 and rearrangement of SET-NUP214 in T-cell acute lymphoblastic leukemia

Haematologica, 2011
Background Mutations in the PHF6 gene were recently described in patients with T-cell acute lymphoblastic leukemia and in those with acute myeloid leukemia.
Qian Wang, Huiying Qiu, Hui Jiang, Lili Wu, Shasha Dong, Jinlan Pan, Wenjuan Wang, Nana Ping, Jing Xia, Aining Sun, Depei Wu, Yongquan Xue, Hans G. Drexler, Roderick A. F. MacLeod, Suning Chen   +14 more
doaj   +1 more source

Clinical validation of a real‐time machine learning‐based system for the detection of acute myeloid leukemia by flow cytometry

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Machine‐learning (ML) models in flow cytometry have the potential to reduce error rates, increase reproducibility, and boost the efficiency of clinical labs. While numerous ML models for flow cytometry data have been proposed, few studies have described the clinical deployment of such models.
Lauren M. Zuromski, Jacob Durtschi, Aimal Aziz, Jeffrey Chumley, Mark Dewey, Paul English, Muir Morrison, Keith Simmon, Blaine Whipple, Brendan O'Fallon, David P. Ng   +10 more
wiley   +1 more source

Intrachromosomal amplification of chromosome 21 (iAMP21) detected by ETV6/RUNX1 FISH screening in childhood acute lymphoblastic leukemia: a case report

Revista Brasileira de Hematologia e Hemoterapia, 2013
Chromosome abnormalities that usually define high-risk acute lymphoblastic leukemia are the t(9;22)/ breakpoint cluster region protein-Abelson murine leukemia viral oncogene homolog 1, hypodiploid with < 44 chromosomes and 11q23/ myeloid/lymphoid ...
Daniela Ribeiro Ney Garcia, Alejandro Mauricio Arancibia, Raul C. Ribeiro, Marcelo Gerardin Poirot Land, Maria Luiza Macedo Silva   +4 more
doaj   +1 more source

Detection of circulating tumor cells is achieved by flow cytometry in melanoma patients

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Melanoma is an aggressive skin tumor whose incidence is rising sharply, and for which the determination of new prognostic factors is a major challenge. In oncology, circulating tumor cells (CTCs) are at the heart of much research, as they represent a source of tumor material obtained non‐invasively by liquid biopsy.
Ludivine Fourdrain, Théo Brochet, Valentin Clichet, Guillaume Chaby, Brigitte Gubler, Loïc Garçon, Jean‐Philippe Arnault, Thomas Boyer   +7 more
wiley   +1 more source

Update on preclinical models of cancer therapy‐related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio‐Oncology, and the ESC Working Group on Cellular Biology of the Heart

European Journal of Heart Failure, EarlyView.
New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the ...
Alessandra Ghigo, Pietro Ameri, Aarti Asnani, Edoardo Bertero, Rudolf A. de Boer, Dimitrios Farmakis, Arantxa González, Stephane Heymans, Borja Ibáñez, Teresa López‐Fernández, Alexander R. Lyon, Piero Pollesello, Amina Rakisheva, Konstantinos Stellos, Katrin Streckfuss‐Bömeke, Carlo Gabriele Tocchetti, Thomas Thum, Peter van der Meer, Eva Van Rooij, Piotr Ponikowski, Marco Metra, Giuseppe Rosano, Sophie Van Linthout   +22 more
wiley   +1 more source

Synthetic Biology‐Based Engineering Living Therapeutics for Antimicrobial Application

Exploration, EarlyView.
This perspective highlights synthetic biology‐driven antibacterial strategies, focusing on three innovative approaches: engineered bacteriophages for precision bacterial targeting, reprogrammed microbes that detect quorum‐sensing signals or metabolites to release antimicrobials, and engineering mammalian cells that recognize pathogen‐associated ...
Shun Huang, Shuihao Zhao, Haijie Zhao, Mingzhang Wen, Zhong Guo   +4 more
wiley   +1 more source